ArticleNew microbes and new infections2025
Investigation of colistin heteroresistance in multidrug-resistant
Article in New microbes and new infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Beyond susceptibility results: understanding the clinical and diagnostic burden of bacterial heteroresistance.Molecular biology reports · 2026Review
- Beyond minimum inhibitory concentration values: clinical and diagnostic challenges of colistin heteroresistance in Acinetobacter baumannii.Molecular biology reports · 2026Review
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Molecular Characterization of Colistin-Resistant ClinicalAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colistin is considered a last-resort antibiotic against Methods: One hundred clinical Results: All isolates were multidrug-resistant, and more than 85 % of the isolates were resistant to all antibiotics tested except colistin (colistin MIC ≤1 mg/L). Eleven colistin-heteroresistant isolates were found. All heteroresistant isolates were also resistant to imipenem. The time-kill assay indicated at 1 × MIC and 2 × MIC concentrations, the three heteroresistant isolates showed noteworthy regrowth at 6 and 12 h, respectively. All of the isolates were negative for Conclusion: Our research indicates that resistant subpopulations may develop during colistin monotherapy. These findings highlight the importance of continuous surveillance, the use of combination therapy, and the development of new strategies to combat
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.